Ontiq

Ontiq is a biotechnology company focused on decoding the complexities of the human immune system to develop next-generation precision medicines. The company utilizes a proprietary high-throughput platform to map the interactions between T-cell receptors (TCRs) and their cognate peptide-MHC targets with unprecedented resolution. By building a comprehensive "immunome" map, Ontiq aims to accelerate the discovery and development of TCR-engineered T-cell (TCR-T) therapies and other immune-modulating biologics. Their technology integrates synthetic biology, protein engineering, and machine learning to identify potent and specific therapeutic candidates for oncology, autoimmunity, and infectious diseases. Ontiq's approach seeks to overcome historical challenges in TCR discovery, such as cross-reactivity and target identification, to deliver safer and more effective immunotherapies.